PDCD1 and acute myeloid leukemia: The “in vitro” data correlates to a clinical study in AML, showing that the azacytidine (AZA)-induced demethylation of PD-1 promoter translates into the increased expression of PD-1 and an unfavorable outcome in the absence of immunotherapy [122].